Synopsis: PL Capital has recommended Adani Ports & SEZ Ltd and Ajanta Pharma, citing strong growth prospects. Adani Ports carries a target of ₹1,876 with 27.34% upside, while Ajanta Pharma has a target of ₹3,200, implying 12.39% potential upside.
Two stocks recommended by PL Capital offer strong upside potential of up to 27.34 percent. The brokerage has identified companies with solid fundamentals, improving earnings visibility, and supportive industry trends.
These recommendations aim to help investors spot attractive opportunities in the current market and understand the key factors that could drive meaningful gains in the coming months. Here are a few stocks recommended by PL Capital with a high growth potential of up to 27 percent:
Adani Ports & Special Economic Zone Limited
With a market capitalization of Rs. 3,19,268.54 crore, the shares of Adani Ports & Special Economic Zone Limited were currently trading at Rs. 1,478 per equity share, rising nearly 0.32 percent from its previous day’s close price of Rs. 1,473.25.
PL Capital, a prominent brokerage firm, has recommended a “Buy” call on Adani Ports & Special Economic Zone Limited with a target price of Rs. 1,876 per share, indicating an upside potential of 27.34 percent from its previous day’s close price of Rs. 1,473.25.
Rationale: PL Capital remains positive on Adani Ports & Special Economic Zone Limited after the completion of the North Queensland Export Terminal (NQXT) acquisition, which strengthens the company’s international business.
NQXT is a high-quality export terminal with more than 65% EBITDA margins, a long 85-year lease life, and stable dollar-linked cash flows under take-or-pay contracts. Acquired at around 17x FY25 EV/EBITDA, the deal is largely balance-sheet neutral and improves long-term revenue visibility and margin profile.
In addition, strong operating performance at domestic ports has supported PL Capital’s positive view. Higher volumes at KP and Gangavaram ports, improved margins in line with the first-half performance, and better revenue traction in harbour and logistics businesses have led to a 5-6 percent upgrade in FY26-28 earnings estimates. These factors together support sustained growth, improved profitability, and form the key rationale behind PL Capital’s target on the stock.
Company Overview:
Adani Ports & Special Economic Zone Limited was incorporated in 1998 and is engaged in operating ports, terminals, logistics, and SEZs, handling 633 MT of cargo annually. It manages 15 ports across India’s coast, providing container, bulk, and multi-modal transport solutions.
Coming into financial highlights, Adani Ports & Special Economic Zone Limited’s revenue has increased from Rs. 7,067 crore in Q2 FY25 to Rs. 9,167 crore in Q2 FY26, which has grown by 29.72 percent. The net profit has also grown by 29.30 percent from Rs. 2,413 crore in Q2 FY25 to Rs. 3,120 crore in Q2 FY26.
Ajanta Pharma Limited
With a market capitalization of Rs. 35,862.77 crore, the shares of Ajanta Pharma Limited were currently trading at Rs. 2870.50 per equity share, rising nearly 0.82 percent from its previous day’s close price of Rs. 2,847.20.
PL Capital, a prominent brokerage firm, has recommended a “Buy” call on Ajanta Pharma Limited with a target price of Rs. 3,200 per share, indicating an upside potential of 12.39 percent from its previous day’s close price of Rs. 2,847.20.
Rationale: PL Capital remains positive on Ajanta Pharma after it signed an in-licensing agreement with Biocon to market semaglutide in 26 Rest-of-the-World (RoW) countries. Ajanta will handle regulatory approvals and leverage its strong distribution network and field force, which is expected to help gain market share and deliver healthy margins. The drug is estimated to add around Rs. 2 billion in sales by FY28E.
In addition, Ajanta generates a strong annual free cash flow of Rs. 8-10 billion, supporting future investments and possible acquisitions. The company is expected to deliver an EBITDA/PAT CAGR of 17%/14% over FY25-28E, with a healthy RoE/RoCE of 28.1%/35.5%.
Company Overview:
Ajanta Pharma Limited was established in 1973 in Mumbai by Purushottam Agrawal and his family. The company is engaged in developing, manufacturing, and marketing branded generic pharmaceuticals, focusing on ophthalmology, dermatology, cardiology, and pain management therapies. It operates and supplies products to over 30 countries, with strong export presence in Asia, Africa, and the US.
Coming into financial highlights, Ajanta Pharma Limited’s revenue has increased from Rs. 1,187 crore in Q2 FY25 to Rs. 1,354 crore in Q2 FY26, which has grown by 14.07 percent. The net profit has also grown by 20.37 percent from Rs. 216 crore in Q2 FY25 to Rs. 260 crore in Q2 FY26.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Brokerage turns bullish on Adani Ports and Ajanta Pharma; Here’s the upside appeared first on Trade Brains.